Webinar: Development of Gene Therapy for Genetic Hearing Loss
Development of Gene Therapy for Genetic Hearing Loss
3:00 PM EDT, July 21, 2022
According to the WHO, hearing loss is the most common neurological disorder worldwide, affecting approximately 400 million people. Currently, the most frequently used treatment for hearing disorders involves hearing rehabilitation using hearing devices. Recent advances in gene therapy provided a promising treatment modality for genetic hearing loss by overcoming the functional deficits caused by the underlying genetic mutations. Thus, gene therapy is capable of restoring hearing functions.
Creative Biolabs has invited Dr. Jeffrey R. Holt to walk us through how gene therapy has become a promising treatment for genetic hearing loss and how his team developed unique gene therapy strategies for genetic hearing loss.
During this webinar, we will discuss the following key points:
- Hearing loss affects ~400 million people worldwide but there is no biological treatment available
- Gene therapy for genetic hearing loss is a promising treatment modality
- The development of gene therapy to treat two forms of genetic hearing loss
Webinar Recording
Speaker
Jeffrey R. Holt, PhD
Professor, Otolaryngology & Neurology at Boston Children's Hospital
Professor, Otolaryngology & Neurology at Harvard Medical School
Jeff Holt is a Professor and Director of Research in the Department of Otolaryngology at Boston Children's Hospital and Harvard Medical School. His lab studies the genetics and physiology of sensory hair cells in the inner ear and has contributed to identification of TMC1 as the protein that converts sound into electrical signals in the inner ear. Translational work in Jeff's lab is focused on gene therapy for genetic hearing loss using gene replacement, gene editing and base editing. He earned a Ph.D. at the University of Rochester in 1995 and has been working in the field for the past 25 years.
